Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations

Carcinogenesis

Volumn 30, Issue 11, 2009, Pages 1923-1926

  Itano, Osamu ^a   Yang, Kan ^a   Fan, Kunhua ^a   Kurihara, Naoto ^a   Shinozaki, Hiroharu ^a   Abe, Sadanori ^a   Jin, Bo ^b   Gravaghi, Claudia ^a   Edelmann, Winfried ^b   Augenlicht, Leonard ^c   Kopelovich, Levy ^d   Kucherlapati, Raju ^e   Lamprecht, Sergio ^a   Lipkin, Martin ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; PROTEIN MLH1; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFICACY; EXON; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HETEROZYGOSITY; INTESTINE TUMOR; MALE; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMATOUS POLYPOSIS COLI; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CECUM; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTESTINE, SMALL; MICE; MUTATION; NUCLEAR PROTEINS; SULINDAC;

EID: 70849089275     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp200     Document Type: Article

References (44)

1. Labayle,D. et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101 635-639.
2. Nugent,K.P. et al. (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 80, 1618-1619.
3. Giardiello,F.M. et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
4. Giardiello,F.M. et al. (1996) Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors. Gut, 38, 578-581.
5. Winde,G. et al. (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment: Advantages of a low-dose non steroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis. Colon Rectum, 38, 813-830.
6. Cruz-Correa,M. et al. (2002) Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology, 122, 641-645.
7. Keller,J.J. et al. (1999) Rectal epithelial apoptosis in familial adenomatous polyposis with sulindac. Gut, 45, 795-796.
8. Giardiello,F.M. et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346, 1054-1059.
9. Meyskens,F.L. et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev. Res., 1 32-38.
10. Niv,Y. et al. (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology, 107, 854-857.
11. Lynch,H.T. et al. (1995) Rectal cancer after prolonged sulindac chemoprevention. Cancer, 75, 936-938.
12. Matsubashi,N. et al. (1998) Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am. J. Gastroenterol., 93, 2261-2266.
13. Tonelli,F. et al. (2000) Long term treatment with sulindac in familial adenomatosis polyposis: Is there an actual efficacy in prevention of rectal cancer? J. Surg. Oncol., 74, 15-20.
14. Boolbol,S.K. et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
15. Beazer-Barclay,Y. et al. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 17, 1757-1760.
16. Chiu,C.H. et al. (1997) Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosysnthesis. Cancer Res., 57, 4267-4273.
17. Yang,K. et al. (2003) Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis, 24, 605-611.
18. 1638N/+ mice. Anticancer Res., 27, 3807-3812.
19. Yang,K. et al. (2005) Sulindac induces benign and malignant tumors with increased COX-2 expression in the proximal colon of normal C57Bl/6 mice. Proc. Am. Assoc. Cancer Res., 46, 1427.
20. Fodde,R. et al. (1994) A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl Acad. Sci. USA, 91, 8969-8973.
21. Edelmann,W. et al. (1999) Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res., 59, 1301-1307.
22. Boivin,G.P. et al. (2003) Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology, 124, 762-777.
23. Suzuki,K. et al. (2007) Sulindac rapidly induces inflammation and neoplasms in the intestine of A/J mice. Proc. Am. Assoc. Cancer Res. 48, 2007.
24. Bjarnason,I. et al. (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology, 104, 1832-1847.
25. Higuchi,K. et al. (2009) Present status and strategy of NSAIDs-induced small bowel injury. J. Gastroenterol. (epub ahead of print).
26. Lanas,A. et al. (2006) Microbial flora in NSAID-induced intestinal damage: A role for antibiotics? Digestion, 73 (suppl. 1), 136-150.
27. Bjarnason,I. et al. (2009) Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J. Gastroenterol., 44 (suppl. XIX), 23-29.
28. Minami,T. et al. (2005) Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin. Cancer Res., 11, 5248-5256.
29. Seo,S.-K. et al. (2007) Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis 12, 195-209.
30. Adachi,M. et al. (2007) Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells. Histol. Histopathol., 22, 437-442.
31. Sun,Y. et al. (2009) Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2 independent cell death. Carcinogenesis, 30, 93-100.
32. Hussain,S.P. et al. (2003) Radical causes of cancer. Nat. Rev. Cancer, 3, 276-285.
33. Chang,C.L. et al. (2002) Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol., 283 148-154.
34. 44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol. Cancer Ther. 4, 51-59.
35. Kumar,S. et al. (2003) p38 MAP kinases: Key signaling molecules are therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov., 2, 717-726.
36. Saklatvala,J. (2004) The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol., 4, 372-377.
37. Cuenda,A. et al. (2007) P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta, 1773, 1358-1375.
38. Cohen,P. (2009) Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol., 21, 317-324.
39. Mantovani,A. et al. (2008) Cancer-related inflammation. Nature 454, 436-444.
40. Yang,G.Y. et al. (2009) Inflammatory bowel disease: A model of chronic inflammation-induced cancer. Methods Mol. Biol., 511 193-233.
41. Colotta,F. et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis, 30, 1061-1073.
42. Cooper,H.S. et al. (2001) The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology, 121, 1407-1416.
43. Tanaka,T. et al. (2006) Dextran sodium sulfate strongly promotes Iolorectal carcinogenesis in Apc (Min/+): Mice: inflammatory stimuli by dextran sodium sulfate results in the development of multiple colonic neoplasms. Int. J. Cancer, 118, 25-34.
44. Huang,E.H. et al. (2006) Induction of inflammatory bowel disease accelerates adenoma formation in Min+/- mice. Surgery, 139, 782-788.